Photo by Tada Images from Shutterstock.com
Moderna is one of the US government’s top pharmaceutical and biotechnology contractors. It quickly became a leader in creating novel mRNA technology and therapies for treating diseases and became successful in federal contracts. Since the COVID-19 epidemic, the company has taken the lead and won several significant contracts. Find more about the best Moderna government contracts here!
1. Moderna Clinched a Vaccine Development Contract for the Biomedical Advanced Research and Development Authority (BARDA)
Photo by PKStockphoto from Shutterstock.com
- Contracting Activity: Biomedical Advanced Research and Development Authority (BARDA)
- Value: $483 million
- Contract type: Modification contract
- Contract Date: April 2020
The Biomedical Advanced Research and Development Authority (BARDA) awarded Moderna a $483 million contract in April 2020 to expedite the development of the mRNA-1273 vaccine for COVID-19. The vaccine was developed clinically, advanced, and manufactured with BARDA funding from 2020 until the phase I clinical study and FDA licensure. Moderna hires roughly 150 new employees to speed up its production capabilities, control its scale-up procedure, and support its entire clinical development. BARDA’s total funding is recorded to be at about $955 million.
2. Moderna to Produce 100 Million Doses of COVID-19 Vaccine
Photo by oasisamuel from Shutterstock.com
- Contracting Activity: Health and Human Services Department
- Value: $1.53 Billion
- Contract type: Firm-fixed-price
- Contract Date: August 2020
A deal for the production of 100 million doses of the COVID-19 mRNA vaccine was obtained by Moderna. Work began in Cambridge, Massachusetts, and was completed on March 31, 2022. Moderna was granted $1.53 billion in funding at the time of the award.
The Army Contracting Command requested an additional 100 million doses of the COVID-19 vaccination by July 31, 2021. The total worth of this additional contract is $1.65 million. Moderna was given a $3.3 billion contract to produce an additional 200 million dosages of the COVID-19 vaccine by March 31, 2022.
3. Moderna to Produce an Additional 100 Million Doses of COVID-19
Photo by tunasalmon from Shutterstock.com
- Contracting Activity: National Institutes of Health and the Biomedical Advanced Research and Development Authority
- Value: $1.97 Billion
- Contract type: Contract modification
- Contract Date: December 2020
ModernaUS Inc., Cambridge, Massachusetts, received a $1.97 billion modification to purchase 100 million filled drug manufacturing doses of SARS-CoV-2 mRNA-1273 vaccine using Option 1 and acetate work on the base and option. The company’s mRNA vaccines against COVID-19 will be produced under a six-month contract extension.
4. SARS-CoV-2 mRNA-1273 vaccines for the US ArmyÂ
Photo by Aleksandar Malivuk from Shutterstock.com
- Contracting Activity: United States Army Contracting Command
- Value: $1.65 Billion
- Contract type: Modification contract
- Contract Date: February 2021
Moderna received a $1.65 billion modifications contract award from the United States in February 2021. The company commits 300 million SARS-CoV-2 mRNA-1273 dosages, in addition to 100 million doses. The subsequent delivery batch, initially due in September to achieve the supply target, was set for July 2021.
5. COVID-19 Vaccine Production Contract with the United States Army
Photo from U.S. Army Official Website
- Contracting Activity: United States Army Contracting Command
- Value: $3.3 Billion
- Contract type: Contract modification
- Contract Date: June 2021
Moderna received a $3.3 billion contract award from the United States in June 2021. As per the contract, Moderna needs to have produced 200 million doses of the double-shot SARS-CoV-2 mRNA-1273 vaccine by March 2022. The grant covered research, development, and testing for the vaccine.
The Biden administration’s objective to get at least 70% of American adults partly immunized by the first week of July was replaced with this campaign department.
6. Bivalent COVID-19 Booster Vaccine Supply
Photo by Wetzkaz Graphics from Shutterstock.com
- Contracting Activity: United States Army Contracting Command
- Value: $1.74 Billion
- Contract type: Firm-fixed-price
- Contract Date: July 2022
Moderna’s most recent deal with the U.S. government is a $1.74 billion contract awarded in July 2022 to develop and deliver 66 million doses of bivalent COVID-19 booster vaccine, getting supply ready for the upcoming winter.
The bivalent vaccination booster, known as mRNA-1273.222, contains the mRNA of the Omicron BA.4/5 strain as well as Spikevax. It targets the viral variety known as omicron, which has dominated the nation throughout December of the previous year. Future delivery to the government agreement is permitted up to 234 million doses under the contract details.
About Moderna Inc.
Moderna Inc. is a Cambridge, Massachusetts-based pharmaceutical company led by a team of dedicated Moderna leaders and executives whose expertise provides the groundwork for breakthroughs in mRNA science. Stéphane Bancel, CEO since October 2011, founded the company in 2010. With a reported revenue of $3.4 billion in the third quarter of 2022, Moderna is ranked 195th among the Fortune 500 businesses in 2022.
